

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
10 May 2001 (10.05.2001)

PCT

(10) International Publication Number
WO 01/32031 A2

- (51) International Patent Classification⁷: A23L 1/00 (74) Agents: GOLDEN, Matthew, J. et al.; Fitzpatrick, Cella, Harper & Scinto, 30 Rockefeller Plaza, New York, NY 10112 (US).
- (21) International Application Number: PCT/US00/30350
- (22) International Filing Date:
3 November 2000 (03.11.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/163,383 4 November 1999 (04.11.1999) US
60/198,449 19 April 2000 (19.04.2000) US
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant (*for all designated States except US*): MON-SANTO COMPANY [US/US]; 800 North Lindbergh Boulevard, St. Louis, MO 63167 (US).
- (71) Applicants and
- (72) Inventors: MENON, Vinod, P. [IN/US]; 11567 Tivolin Lane, St. Louis, MO 63146 (US). KINLEN, Patrick, J. [US/US]; 1348 Remington Oaks Terrace, St. Louis, MO 63026 (US). PIRAKITIKULR, Pichai [IN/US]; 455 Morningside Drive, Crown Point, IN 46307 (US).
- Published:**
— *Without international search report and to be republished upon receipt of that report.*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 01/32031 A2

(54) Title: CHOLESTEROL REDUCING STEROL COMPOSITIONS, PREPARATION AND METHOD OF USE

(57) Abstract: A composition comprising a mixture of a phytosterol and/or phytosterol ester and a surfactant(s). The surfactants are selected from the group consisting of anionic, cationic, nonionic, and zwitterionic surfactants. The phytosterol is selected from the group consisting of sitosterol, campesterol, brassicasterol, stigmasterol, clionasterol and mixtures thereof. The phytosterol esters are derivatives of the aforementioned phytosterols. The invention is also directed to a method of making the disclosed compositions, and to non-fat containing food products including the disclosed compositions.

Cholesterol Reducing Sterol Compositions, Preparation and
Method of Use

5

BACKGROUND

Field of the Invention

10 This invention relates to plant sterol compositions and
its derivatives for reduction of cholesterol absorption.
More particularly, the invention provides compositions
containing a phytosterol and/or a phytosterol ester and
surfactant(s) that are useful for reducing cholesterol
absorption. The invention also relates to methods of
15 preparing such compositions for reducing cholesterol
absorption.

Related Background Art

20 Cholesterol, while an essential nutrient for humans, is
well known to be a leading cause of death in the United
States and most countries around the world. Many foods
consumed today have high cholesterol content. Once the
cholesterol reaches the small intestine it can be
25 absorbed which results in an increase in serum
cholesterol levels. The serum cholesterol is well-known
to be deposited in various parts of the circulatory
system, for example, in soft tissues. The long-term
accumulation or build-up of cholesterol deposits leads to
30 atherosclerotic disease.

-2-

By reducing cholesterol content of food, as well as inhibiting the absorption of cholesterol, it has been possible to reduce serum levels of cholesterol. One of the areas that has been explored to control serum cholesterol levels is the use of dietary supplements, such as cholestyramine resin, probucol, colestipol HCl, nicotinic acid, mevinolin, pectin, guar gum, and oat bran. Another area, that has received considerable attention, has been the development of food additives that reduce the absorption of cholesterol in the small intestine. Prevention of the absorption of cholesterol results in lower levels of cholesterol in the blood and thus helps to prevent the formation of atherosclerotic plaques.

Plant sterols have been found to be particularly effective at reducing serum cholesterol levels. In particular, studies conducted employing beta-sitosterol were found to produce significant reductions (17%) in the amounts of cholesterol in the blood (Farquhar, J.W. et al., Circulation, 14, 77-82 (1956)). However, large doses of beta-sitosterol were required, 12-18 grams per day. This is a major impediment to the use of beta-sitosterol for cholesterol reduction. A related class of compounds, plant stanols (saturated plant sterols), have also been found to be effective for reducing cholesterol absorption. It has been postulated that plant sterols (stanols) block cholesterol absorption by competing with cholesterol for bile acid micellization. As a result of this competition between plant sterols and cholesterol, it is believed that plant sterols displace cholesterol from the micellar phase and thereby prevent

-3-

its absorption in the small intestine.

Plant stanols and sterols have represented particularly attractive classes of compounds for use in lowering serum cholesterol levels, since they are natural components of vegetable fats and oils. Additionally, plant stanols and sterols are absorbed in very small quantities compared to the absorption of bile and dietary cholesterol. In fact, sitostanol is considered to be practically unabsorbable, i.e., less than 5%. Although, plant sterols and stanols are attractive as cholesterol absorption inhibitors, they have proven to be difficult to formulate. A major factor in these difficulties has been the fact that plant sterols are virtually insoluble in water. Considerable efforts have been made to develop plant sterol or stanol preparations that can easily be formulated with consumer food products.

U.S. Patent No. 5,244,887 is directed to plant stanol food additives for reducing the absorption of cholesterol in the gastro-intestinal tract. The greatest effectiveness was obtained when the stanols were evenly distributed in finely divided form throughout the food product or beverage to which it is added. This was accomplished by dissolution of the stanols or by suspension of the stanols in an emulsion. Solubilizing agents listed for the stanols include vegetable oil, monoglycerides, diglycerides, triglycerides, tocopherols, and the like and mixtures thereof. Suspensions or emulsions of stanols include water, alcohols, polyols, and other edible compounds. Dispersing agents may be used to aid in the formation of suspensions, such as

-4-

lecithin, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, polysorbate 85, sodium lauryl sulfate, and the like. The stanol food additives are used with cholesterol containing foods, such as meats, eggs and dairy products.

EP 0 897 671 discloses aqueous dispersions of high melting lipids, such as plant sterols, with non-sterol emulsifiers. Emulsifiers used to disperse the high melting lipids include polyglycerol esters and tweens, especially polysorbate 60. Mono- and diglycerides are also mentioned as suitable emulsifiers. The dispersions have reduced size on the order of 15 microns or lower. The dispersions are said to be useful in spreads and other food products. Additionally, the dispersions provide structure to the food products and their use can apparently permit minimization or elimination of saturated fats and trans fatty acids.

There is a continuing need for formulations which lower serum cholesterol levels by preventing or significantly reducing the absorption of cholesterol. Such formulations would desirably be able to be delivered in a variety of ways to individuals, e.g., as an additive to food products or as a pill for oral administration. Furthermore, in order for the formulations to be most effective in lowering cholesterol absorption, the formulation must reach the gastrointestinal tract so that they can be rapidly and efficiently solublized in the micellar phase thereby preventing the absorption of cholesterol. It has now been discovered that formulations comprising a plant sterol or a plant sterol

-5-

ester and a surfactant(s) are effective at inhibiting the absorption of cholesterol.

SUMMARY OF THE INVENTION

5

10

15

Compositions for inhibiting the absorption of cholesterol are disclosed. The compositions comprise a plant sterol and/or a plant sterol ester and a surfactant(s). The surfactant(s) is selected from the group consisting of anionic, cationic, nonionic and zwitterionic surfactants. Examples of plant sterols that may be employed include sitosterol, campesterol, brassicasterol, stigmasterol, clionasterol and mixtures thereof. The compositions of the present invention provide an effective method of reducing cholesterol without any adverse side-effects.

20

25

30

The compositions of the present invention can be used as food additive compositions for reducing cholesterol absorption from foods. The food additive composition may be employed in small quantities making it convenient for use and also an inexpensive method to reduce cholesterol absorption. The food additive compositions of the present invention are storage-stable for extended periods of time. The food additive compositions may be added before, during or after cooking with foods. The food additive compositions may be added to food products during production prior to sale to the consumer. Advantageously, the compositions of the present invention can be used in non-fat containing foods.

The present invention also contemplates various combinations of the foregoing surfactant(s) and a

-6-

phytosterol and/or a phytosterol ester being administered orally in any of the usual solid forms such as pills, tablets, capsules or powders, including sustained release preparations.

5

DETAILED DESCRIPTION OF THE INVENTION

10

15

The present invention relates to the use of plant sterol and/or plant sterol ester compositions that inhibit the absorption of cholesterol. More particularly, the invention relates to the formation of water soluble/dispersible sterol and/or sterol ester systems comprising a plant sterol and/or a plant sterol ester and anionic, cationic, nonionic, or zwitterionic surfactant systems, which reduce cholesterol absorption.

20

25

The terms "phytosterols" and "sterols" are used herein interchangeably. The phytosterols used in the present invention typically may include sitosterol, campesterol, brassicasterol, stigmasterol, clionasterol and mixtures thereof. Generally, the phytosterols in the present invention will be a mixture of two or more of such phytosterols. The phytosterols are preferably present in the free form. However, in some instances, the phytosterols may be in the naturally occurring ester form. It will also be appreciated that modifications of the plant sterols are also well within the scope of the present invention, for example, small side chains.

30

The terms "phytosterol ester" and "sterol esters" are used herein interchangeably. The term "sterol ester" as used herein refers to plant sterols that has been

-7-

modified to form a plant sterol ester derivative.

Sterols and their ester derivatives are well known in the art and are described "Analysis of Sterols" by L.J. Goad and T. Akihisa, (published by Blackie Academic & Professional, in imprint of Chapman and Hall, United Kingdom, 1997) hereby incorporated by reference.

A larger number of inexpensive sources of plant sterols are known. These include, vegetable oils, vegetable oil sludge, vegetable oil distillates, and other plant oil sources such as tall oils. For example, a preparation of sterols from vegetable oil sludge by using solvents such as methanol is taught in U.S. Pat. No. 4,420,427.

Sterols isolated from plant sources are usually mixtures of several different sterols.

Sitosterol may be obtained from cold pressed wheat germ oil, soy extract, or rice extract. (It will be appreciated that natural sitosterol contains about 40% alpha-sitosterol and about 60% beta-sitosterol.)

In another embodiment of the present invention, plant stanols and/or plant stanol esters and mixtures may be used in the disclosed formulations of the present invention. Applicants hereby incorporate by reference the entire disclosure of attorney docket 775.4800, U.S. Serial No. 60/163,382, filed November 4, 1999, and the entire disclosure of attorney docket 775.5100, U.S. Serial No. 60/198,326, filed April 19, 2000, both entitled "Cholesterol Reducing Stanol Compositions, Preparation and Method of Use".

-8-

The surfactants to be employed according to the invention can be anionic, cationic, nonionic, zwitterionic and mixtures thereof. Suitable anionic surfactants include AOT, also known as sodium dioctylsulfosuccinate or sodium docusate, ammoniated glycyrrhizin, and sodium stearyl lactylate. Nonionic surfactants include, polyoxyethylene castor oil (cremophor EL polyoxyl 35 castor oil), polyethylene glycol "PEG" (low molecular weight 1000 to 4000), diacetyl lactic acid of esters of mono- and diglycerides, diacetyl tartaric acid esters of mono- and diglycerides, monosodium phosphate derivatives of mono- and diglycerides, ethoxylated mono- and diglycerides, polyethylene glycol (8) stearate, polyethylene glycol (40) stearate, sorbitan esters of fatty acids, quillaja saponin, ethylene oxide propylene oxide block copolymers, vitamin E TPGS (d-alpha tocopheryl polyethylene glycol 1000 succinate), fatty alcohols and sucrose fatty acid esters, such as sucrose stearate, sucrose distearate, sucrose palmitate.

Preferred fatty alcohols include but are not limited to the following, 1-decanol ($\text{CH}_3(\text{CH}_2)_8\text{CH}_2\text{OH}$) also known as n-decyl alcohol, 1-dodecanol ($\text{CH}_3(\text{CH}_2)_{10}\text{CH}_2\text{OH}$) also known as dodecyl or lauryl alcohol, 1-tetradecanol ($\text{CH}_3(\text{CH}_2)_{12}\text{CH}_2\text{OH}$) also known as myristyl alcohol, 1-hexadecanol ($\text{CH}_3(\text{CH}_2)_{14}\text{CH}_2\text{OH}$) also known as cetyl or palmityl alcohol, 1-octadecanol ($\text{CH}_3(\text{CH}_2)_{16}\text{CH}_2\text{OH}$) also known as stearyl alcohol, 9-octadecen-1-ol ($\text{CH}_3(\text{CH}_2)_7\text{CH}=\text{CH}(\text{CH}_2)_7\text{CH}_2\text{OH}$) also known as oleyl alcohol, 1-eicosanol ($\text{CH}_3(\text{CH}_2)_{18}\text{CH}_2\text{OH}$) also known as arachidyl alcohol, 1-docosanol ($\text{CH}_3(\text{CH}_2)_{20}\text{CH}_2\text{OH}$) also known as behenyl alcohol, 1-hexacosanol ($\text{CH}_3(\text{CH}_2)_{24}\text{CH}_2\text{OH}$), 1-octacosanol ($\text{CH}_3(\text{CH}_2)_{26}\text{CH}_2\text{OH}$) also know

-9-

as octacosyl alcohol (wheat leaf wax), 1-triacontanol ($\text{CH}_3(\text{CH}_2)_{28}\text{CH}_2\text{OH}$) also known as melissyl alcohol (beeswax as stearate). A particularly preferred fatty alcohol is 1-octadecanol.

5

Zwitterionic surfactants include, hydroxylated lecithin and the like.

10

Other anionic surfactants such as sodium stearate, sodium palmitate, sodium laurate, sodium myristate, sodium linoleate, and potassium oleate may also be employed.

15

Additional nonionic surfactants that may be included in the compositions of the present invention include polyglycerol esters and tweens, polysorbate 20 (tween 20), polysorbate 40 (tween 40), polysorbate 60 (tween 60), polysorbate 80 (tween 80), polysorbate 85 (tween 85), fatty acids such as oleic acid ($\text{C}_{17}\text{H}_{33}\text{COOH}$), stearic acid ($\text{C}_{17}\text{H}_{35}\text{COOH}$), and palmitic acid ($\text{C}_{15}\text{H}_{31}\text{COOH}$), triglycerides $\text{CH}_3(\text{CH}_2)_6\text{COOH}$ and $\text{CH}_3(\text{CH}_2)_8\text{COOH}$ and mixtures thereof (e.g., MCT oil).

20

25

Naturally occurring polymers such as guar gum, karaya gum, gum arabic, carrageenan, xanthan gum, dextran, maltodextrin, chondroitin sulfate, polyglycerol esters of fatty acids commercially known as Polyaldo, succinoglucan and hyaluronic acid may also be employed in the compositions of the present invention. Synthetic polymers such as poly(vinyl alcohol), poly(vinyl pyrrolidone), hydroxypropyl methyl cellulose, and sodium carboxymethyl cellulose may also be employed in the compositions of the present invention.

30

-10-

Other fatty acids, that may be employed in the present invention, include caprylic, capric, lauric, myristic, myristoleic, palmitoleic, oleic, ricinoleic, linoleic, linolenic, eleostearic, arachidic, arachidonic, behenic and erucic acid. The fatty acids of the present invention can be derived from naturally occurring or synthetic fatty acids; they can be saturated or unsaturated, including positional and geometric isomers, depending on the desired physical properties, for example liquid or solid.

In one preferred embodiment the composition of the present invention comprises a mixture of a phytosterol and a surfactant selected from the group consisting of sodium docusate, ammoniated glycyrrhizin, polyoxyethylene castor oil, polyethylene glycol, diacetyl lactic acid esters of mono- and diglycerides, diacetyl tartaric acid esters of mono- and diglycerides, monosodium phosphate derivatives of mono- and diglycerides, ethoxylated mono- and diglycerides, quillaja saponin, ethylene oxide propylene oxide block copolymers, vitamin E TPGS, hydroxylated lecithin and mixtures thereof. The composition of the present invention may further comprise a surfactant selected from the group consisting of sodium salts of fatty acids, fatty alcohols, polyethylene glycol (8) stearate, polyethylene glycol (40) stearate, sucrose fatty acid esters, tween and mixtures thereof.

One preferred embodiment of the present invention comprises a mixture of a phytosterol and/or a phytosterol ester and fatty acid alcohol, preferably, octadecanol. Another preferred embodiment of the present invention

-11-

comprises a mixture a phytosterol and/or a phytosterol ester, Tween 60 and PEG. Other preferred embodiments include a phytosterol and/or a phytosterol ester, fatty acid alcohol and sucrose fatty acid ester, such as Crodesta.

One preferred embodiment of the present invention provides a method of reducing cholesterol absorption in humans which comprises orally administering an effective amount of a composition of the present invention. The invention also provides for a method for reducing serum cholesterol levels comprising administering a mixture of a phytosterol and/or a phytosterol ester and a surfactant(s).

In another embodiment of the present invention, emulsifiers may be used in the formulation of dispersible sterol and/or sterol ester systems. Preferred emulsifiers include a variety of phospholipids, phosphatidyl choline (PC), phosphatidyl ethanolamine (PE), N-acylphosphatidyl ethanolamine (NAPE), phosphatidyl serine (PS), phosphatidyl inositol (PI), phosphatidyl glycerol (PG), diphosphatidyl glycerol (DPG), phosphatidic acid (PA) and plasmalogen. These and other phospholipids are described, for example, in Szuhaj and List (eds.), Lecithins, American Oil Chemists Society (1985) ("Szuhaj and List"), incorporated herein in its entirety by reference.

The phospholipids may be used individually or in various combinations, and may be obtained from "natural" sources (e.g., soybean lecithin) or from chemical synthesis. The

-12-

phospholipids may be in the form of relatively unpurified mixtures of phospholipids and other constituents (e.g., crude commercial lecithins obtained from the refining of soybean oil and other vegetable oils such as sunflower and canola), or may be purified to various degrees. In addition, phospholipids including those found in crude soybean lecithins or other crude commercial lecithins may be chemically modified. Lecithins, other phospholipid preparations, or individual phospholipids purified from natural sources or obtained by chemical synthesis, contain one or more functional groups susceptible to chemical modification, e.g., carbon-carbon double bonds, esters, phosphonate esters, amines and hydroxyl groups. Chemical modification of phospholipids can be compatible with the present methods. Thus, phospholipids that have been acetylated, hydroxylated, hydrolyzed (e.g., to produce lysophospholipids), hydrogenated, halogenated, phosphorylated, sulfated epoxidated, ethoxylated, or otherwise modified are potentially useful in the present methods and are included within the meaning of the term "phospholipid" as used herein. Various natural and synthetic phospholipids, including various types of lecithins, may be obtained commercially, for example Ultralec from ADM Corp., and other lecithins may be obtained from CALBIOCHEM®, La Jolla, Calif., USA and from SIGMA® Chemical Company, St. Louis, Mo., USA.

In common usage, the term "lecithin" refers to the entire phospholipid fraction obtained from natural sources such as soybean, cotton seed, corn, wheat germ, oat, barley, sunflower, rapeseed, canola, linseed, peanut, palm

-13-

kernel, egg yolk, milk and brain. Generally these fractions include a mixture of polar and neutral lipids with a polar lipid content (as defined by insolubility in acetone) of at least 50%. The art has also used the term "lecithin" as the common name for phosphatidyl choline. The term "lecithin" as used herein refers to the first usage, i.e., the entire phospholipid fraction obtained from selected vegetable oils or other appropriate sources. See, Chapter 2 of Szuhaj and List. It is to be noted, however, that phosphatidyl choline is an appropriate phospholipid for use in the present methods, either alone or in combination with other phospholipids.

Commercial soybean lecithin, a preferred source of phospholipids, is obtained from the refining of soybean oil. Crude soybean oil generally contains about 1.0 to 3.0 weight percent phospholipids. When the crude oil is refined, the first step generally is to remove the phospholipids. This step, often called "degumming," is accomplished by first adding water to the crude oil. The water hydrates the phospholipids and makes them less soluble in the oil. The denser phospholipids and water are then separated from the less-dense oil, typically by centrifugation. Removal of the water from the dense phase results in a product having approximately equal amounts of phosphatidyl choline, phosphatidyl ethanolamine, and inositol phosphatides. Partially refined soybean oil is commonly added back to produce a liquid product that is flowable at room temperature (sometimes called "fluidized lecithin"). Commercial fluid soybean lecithin contains about 50 to about 65 weight percent phospholipids and a small amount.

-14-

(generally less than about 5 weight percent) of various carbohydrates, mineral salts, protein materials, free fatty acids, sterols, and water. The remainder of commercial soybean lecithin is soybean oil.

5

Various lecithin powders enriched for phospholipid content are available commercially and may also be used in the present methods. Such lecithin powders are also within the scope of the term "lecithin" as used herein. The powders are typically derived by fractionation, for example acetone fractionation, of crude lecithins such as commercial soybean lecithin, and may contain from about 60% to over 95% phospholipid.

10

15

Another commercial source of phospholipids is the class of products, resulting from modification of soybean lecithin to improve its hydrophilic properties. Various approaches have been taken to effect these modifications. For example, soybean lecithin may be chemically or enzymatically modified, e.g., via reaction with maleic anhydride. Certain components may be removed from commercial soybean lecithin. Alternatively, another approach is to add various components, for example nonionic emulsifiers, to the commercial soybean lecithin. Such emulsifiers include, without limitation, polyoxyalkylene monoglyceride, polyoxyalkylene diglycerides, and the polyoxyethylene derivatives of partial fatty acid esters. These modified lecithins are also included in the term "lecithin" as used herein.

20

25

30

Hydroxylated lecithin is a preferred embodiment of the phospholipids used in the invention. Hydroxylated

-15-

lecithin is prepared by hydroxylating the double bonds in the fatty acids attached to the phospholipids and glycolipids of lecithin, which can be carried out by reaction with hydrogen peroxide and a weak acid such as lactic acid. Although not wishing to be bound by theory, it is believed that hydroxylation is not specific and can occur at any double bond within any of the lipids. The degree of hydroxylation is typically about 10% but can be varied by methods known to those of ordinary skill in the art.

The compositions of the present invention are preferably formed into a fine dispersion using melt processing. One particular preferred method of melt processing comprises dry-mixing a phytosterol and/or a phytosterol ester and a surfactant(s) together with a stirring device such as a mechanical stirrer, shear mixer, vibrational mixer or sonicator. The mixture is then heated to a temperature sufficient to melt same, but not so high as to degrade the phytosterol, phytosterol ester or surfactant(s). The resulting mixture is then rapidly cooled, e.g., liquid nitrogen, to form a salt like material. While not wishing to be limited by theory, it is believed that the step of melt blending the phytosterol and/or phytosterol ester and surfactant(s) prior to rapid cooling facilitates the formation of a composition that is in a finely dispersed state that is able to reach the small intestine thereby being able to inhibit the absorption of cholesterol.

An alternative variation on the melt processing described above comprises the addition of a surfactant(s) to a

-16-

phytosterol and/or phytosterol ester melt. This may be desirable in cases where the surfactant(s) is thermally unstable and would not survive prolonged heating at high temperatures, i.e., thus the residence time for the surfactant(s) is reduced by its later addition to a melt. Once the surfactant(s) has been added to the melt, the mixture can be treated in a fashion similar to that described previously.

A further alternative procedure to melt blending for forming the compositions of the present invention is high pressure melting. This procedure is also desirable for blending heat sensitive surfactant(s) and phytosterol and/or phytosterol esters. It has been discovered that by using a mixing or compression means allowing for increasing the pressure on the ingredients, the surfactant(s), phytosterol and/or phytosterol esters will melt blend at ambient temperatures. Homogenous mixtures of heat sensitive surfactant(s) and phytosterol and/or phytosterol esters can therefore be formed while avoiding temperatures at which thermal decomposition of ingredients will occur.

One embodiment of high pressure melting is roller compaction. The surfactant(s) and phytosterol and/or phytosterol ester are mixed together as described previously, the mixture is then compressed together under high pressure using a roller. The pressure exerted on the mixture is high enough to result in the flow of the ingredients and surface sintering of the mixture results.

An additional embodiment of high pressure melting is

-17-

extrusion. For example, in an extrusion process, a loosely packed powder mixture of surfactant(s) and phytosterol and/or phytosterol ester, is propelled continuously along a screw through regions of high pressure and controlled temperature. Shear forces from the screw melt and mix the material into a continuous stream of molten material, which is then forced through a die.

The mixture resulting from the high pressure melting process is typically a soft, pliable solid material that can be further processed by cooling to solidify followed by breaking into chips or milling to form a uniform powder for use in the formation of products as described herein.

Mixtures of a phytosterol and/or a phytosterol ester and surfactant(s) may also be processed using solution processing or steric stabilization. Use of solution processing is particularly effective for use with surfactant(s) that are thermally stable. The phytosterol and/or phytosterol ester and surfactant(s) are generally dry mixed together, although this is not always necessary, the resulting solid mixture is then dissolved in an organic solvent, such as methylene chloride. The solvent is then removed to provide an amorphous/dispersible solid form.

Steric stabilization provides an effective method to form a dispersible solid form of a phytosterol and/or phytosterol ester and surfactant(s). A fine dispersion of a phytosterol and/or phytosterol ester is added to

-18-

water containing the surfactant(s). The surfactant(s) in the water help to keep the sterol(s) in suspension. Once a finely divided suspension has formed the water is evaporated off leaving a more readily dispersible solid form.

Preferred embodiments of the present invention include a mixture of from about 10 to about 99.99 weight percent of a phytosterol and/or phytosterol ester and from about 0.01 to about 90 weight percent of a surfactant(s), preferably from about 40 to about 95 weight percent of a phytosterol and/or phytosterol ester and from about 5 to about 60 weight percent of a surfactant(s), and more preferably about 95 weight percent of a phytosterol and/or phytosterol ester and about 5 percent by weight percent of a surfactant(s).

In one preferred embodiment of the present invention, the compositions of the present invention comprise a phytosterol and/or phytosterol ester and at least two surfactants. Such a mixture comprises from about 10 to about 99.99 weight percent of a phytosterol and/or phytosterol ester and the sum of the at least two surfactants is from about 0.01 to about 90 weight percent, preferably such a mixture comprises from about 40 to about 95 weight percent of a phytosterol and/or phytosterol ester and the sum of at least two surfactants is from about 5 to about 60 weight percent, and more preferably about 95 weight percent of a phytosterol and/or phytosterol ester and the sum of at least two surfactants is about 5 weight percent.

-19-

Desirable characteristics of food additive compositions for reducing cholesterol absorption include absence of side effects, efficacy without absorption of the compound, stability at cooking temperatures, stability in storage and in oxidizing environments, low cost, availability, and small dose requirements.

The compositions of the present invention may be orally administered in a variety of forms: uncoated tablets, coated tablets such as film, sugar or gelatin coated, chewable tablets, swallowable tablets (capsules), effervescent tablets, immediate release tablets, sustained (controlled or modified) release tablets; soft gelatin capsules either liquid (non-aqueous) or paste (slurry); hard gelatin capsules in powder (granulation), bead, tablet, liquid, semi-solid, sprinkle (immediate or controlled release) forms; oral liquids such as aqueous, emulsions or suspension; sachets (packages) in powder, granule or sprinkle (immediate or controlled release) forms. Other forms for administering the compositions of the present invention include syrup, fruit beverages, or fruit gelatines.

Although the composition of the invention may be used in various embodiments it may be said, one preferred embodiment is when the compositions of the present invention are evenly distributed in finely divided form throughout the food product or beverage to which it is added. The compositions of the present invention may be added to food products or beverages prior to purchase by the consumer for consumption.

Alternatively, the compositions of the present invention

-20-

may be purchased in bulk form or individually wrapped packages, e.g., 8 oz. servings. A serving from the bulk form, e.g., 8 oz., or the contents of a package may be added to a glass of cold or hot water or other beverage, stirred to dissolve the contents, prior to consumption. Typical beverages include the following, instant ice tea in Orange Pekoe, English Breakfast, Passion Fruit and Hisbiscus Flavors, powdered soft drinks such as Crystal Light and Contry Time Lemonade, Instant Iced Coffee in flavors such as Mocchacchino, Hazelnut, French Vanilla, and Hot Chocolate and Fruit Smoothies.

The compositions of the present invention may also be included in mini-sweets. The mini-sweets will typically be consumed after any and all meals of each day. The mini-sweets will typically contain between 25 and 60 calories and 1 to 3 grams of fat. Mini-sweets include the following varieties: chocolate chews; caramel chews; hard candies such as cinnamon, butterscotch, coffee and fruit flavors; chocolate truffles such as hard dark chocolate on the outside filled with hazelnut creme, irish creme or cappucinno creme; brown bites; cookie chews in peanut butter, chocolate chip or ginger snaps; granola/nutrition bar miniatures such as chocolate covered oat and peanut butter; and chewy breath mints. Mini-sweets may be prepared in individually wrapped packages or in larger containers for multiple uses.

The method by which the novel food additive composition, i.e., the sterol and/or sterol ester and surfactant(s), is used to reduce cholesterol absorption from foods and beverages includes the step of commingling the food

-21-

additive composition with foods and beverages, mixing until uniformly blended.

5 In a preferred method of commingling the indicated food additive with foods and beverages which contain cholesterol, the food additive is added such that the amount of sterols in the food additive is in the ratio of about 1:1 by weight to the cholesterol contained in the foods and beverages. Thus, for a food additive
10 composition which comprises 25% sterols and a food which contains about 0.1% cholesterol (such as hamburger), the ratio of food additive to food product is about 1:250 by weight.

15 The food additive composition of the invention can be commingled with foods by a step selected from the group of infusion, injection, mixing, kneading, blending, immersion, spraying, surface application (for example, brushing and basting), cooking in oils which contain the food additive-invention, and combinations thereof.
20 Preferred steps for commingling the food additive-invention with ground meat are kneading and mixing; for meat pieces such as steaks, chicken breasts, and chopped, diced or sliced meat, the preferred steps
25 are injection, infusion, spraying, immersion, and surface applications such as basting and marinating. Two preferred steps for commingling the food additive-invention with beverages are mixing and blending.

30

The compositions of the present invention will be used as food additives to foods such as meats, eggs and dairy

-22-

products. Generally, when used as food additives, the compositions of the present invention will not contribute substantially to the taste of the food product.

Accordingly, the compositions of the present invention
5 can be used in food products without compromising the food products taste and flavor.

The compositions of the present invention may also be formulated into fine particles which may be sprinkled on
10 to other food products, i.e., dairy products such as ice cream or candy.

The compositions of the invention may be administered to any animal. Foremost among such animals are mammals,
15 e.g., humans, although the invention is not intended to be so limited. The dosage administered will be dependent upon the age, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired.

20 The compositions of the present invention may be administered orally in any of the usual solid forms such as pills, tablets, capsules or powders, including sustained release preparations. The term unit dosage
25 form as used in this specification and the claims refer to physically discrete units to be administered in single or multiple dosage to animals, each unit containing a predetermined quantity of active material, i.e., phytosterol and/or phytosterol ester, in association with
30 a surfactant(s) and a carrier. The quantity of active material is that calculated to produce the desired therapeutic effect upon administration of one or more of

-23-

such units. Of course, it is understood that the exact treatment level will depend upon the case history of the animal, e.g., human being, that is treated. The precise treatment level can be determined by one of ordinary skill in the art without undue experimentation.

The require dosage of the phytosterol and/or phytosterol ester will vary with the severity of the condition and the duration of the treatment. Unit dosages can range from about 0.01 mg/kg to about 500 mg/kg (the unit designated "mg/kg" as used herein refers to mg of phytosterol and/or phytosterol ester per kilogram of body weight), preferably from about 0.1 mg/kg to about 125 mg/kg with up to six doses daily, preferably four dosages daily. Most preferably, the doses are administered at meal times. The dosages may be administered orally in any suitable unit dosage form such as pills, tablets, and capsules. Preferred are capsules made from gelatin.

As used herein, the term "carrier" denotes a solid or liquid filler, diluent, or encapsulating substance. Some examples of the substances that can act as carriers are sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives, such as sodium carboxymethylcellulose, ethylcellulose, cellulose acetate; powdered tragacanth; malt; gelatin; talc; stearic acid; magnesium stearate; calcium sulfate; vegetable oils, such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil and of the broma; polyols such as propylene glycol, glcerin, sorbitol, mannitol, and polyethylene glycol; agar, alginic acid; pyrogen-free water; isotonic saline; ethyl

-24-

alcohol and phosphate buffer solutions, as well as other non-toxic compatible substances used in preparation of formulations. Wetting agents and lubricants such as sodium lauryl sulfate, as well as coloring agents, 5 flavoring agents, and preservatives can also be present. Dye stuffs or pigments may be added to the tablets, for example, for identification or in order to characterize combinations of active doses

10 Other preparations that can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer such as glycerol or sorbitol. The push-fit capsules can contain the active compounds in the form of granules, which may 15 be mixed with fillers such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds are preferably dissolved or suspended in suitable liquids, such as fatty oils, or 20 liquid paraffin. In addition, stabilizers may be added.

Powders are prepared by comminuting the compositions of the present invention to a suitable fine size and mixing with a similarly comminuted diluent pharmaceutical 25 carrier such as an edible carbohydrate material as for example, starch. Sweetening, flavoring, preservative, dispersing and coloring agents can also be present.

Capsules are made by preparing a powder mixture as 30 described above and filling formed gelatin sheaths. A lubricant such as talc, magnesium stearate and calcium stearate can be added to the powder mixture as an

-25-

5 adjuvant before the filling operation; a glidant such as colloidal silica may be added to improve flow properties; a disintegrating or solubilizing agent may be added improve the availability of the medicament when the capsule is ingested.

10 Tablets are made by preparing a powder mixture, granulating or slugging, adding a lubricant and disintegrant and pressing into tablets. A powder mixture is prepared by mixing the compositions of the present invention, suitable comminuted, with a diluent or base such as starch, sucrose, kaolin, dicalcium phosphate and the like. The powder mixture can be granulated by wetting with a binder such as syrup, starch paste, acacia
15 mucilage or solutions of cellulosic or polymeric materials and forcing through a screen. As an alternative to granulating, the powder mixture can be run through the tablet machine and the resulting imperfectly formed slugs broken into granules. The granules can be
20 lubricated to prevent sticking to the tablet forming dies by means of the addition of stearic acid, a stearate salt, talc or mineral oil. The lubricated mixture is then compressed into tablets. The medicaments can also be combined with free flowing inert carriers and
25 compressed into tablets directly without going through the granulating or slugging steps. A protective coating consisting of a sealing coat of shellac, a coating of sugar or polymeric material and a polish coating of wax can be provided. Dye stuffs or pigments may be added to
30 the tablets, for example, for identification or in order to characterize combinations of active doses. In tablet form the carrier comprises from about 0.1% to 99% by

-26-

weight of the total composition.

This invention will be better understood from the Example which follows. However, one skilled in the art will readily appreciate that the specific methods and results discussed are merely illustrative of the invention and no limitation of the invention is implied.

EXAMPLE 1

20 grams of soy sterols was dissolved in 250 ml chloroform with 1.05 grams of octadecanol. The chloroform was evaporated under nitrogen at room temperature yielding a solid mixture containing 5 percent octadecanol. The mixture was cryoground into hamster chow and fed to hamsters at 1 percent stanol equivalent in their diet. The hamsters who consumed the chow with sterol were found to have absorbed less cholesterol than a control group of hamsters that eat hamster chow without sterol.

Other objects, advantages, features, modifications of this invention will be apparent to those of ordinary skill in this art. This invention is not limited except as set forth in the following claims.

-27-

What is claimed is:

1. A composition comprising a mixture of a phytosterol and a surfactant selected from the group consisting of sodium docusate, ammoniated glycyrrhizin, polyoxyethylene castor oil, polyethylene glycol, diacetyl lactic acid esters of mono- and diglycerides, diacetyl tartaric acid esters of mono- and diglycerides, monosodium phosphate derivatives of mono- and diglycerides, ethoxylated mono- and diglycerides, quillaja saponin, ethylene oxide propylene oxide block copolymers, vitamin E TP GS, hydroxylated lecithin and mixtures thereof.
2. The composition of claim 1, further comprising a surfactant selected from the group consisting of sodium salts of fatty acids, fatty alcohols, polyethylene glycol (8) stearate, polyethylene glycol (40) stearate, sucrose fatty acid esters, tween and mixtures thereof.
3. The composition of claim 1, wherein the phytosterol is selected from the group consisting of sitosterol, campesterol, brassicasterol, stigmasterol, clionasterol and mixtures thereof.
4. The composition of claim 3, wherein the sitosterol is alpha-sitosterol or beta-sitosterol.
5. The composition of claim 2, wherein said fatty alcohol is selected from the group consisting of 1-decanol, 1-dodecanol, 1-tetradecanol, 1-hexadecanol,

-28-

1-octadecanol, 9-octadecen-1-ol, 1-eicosanol, 1-docosanol, 1-hexacosanol, 1-octacosanol, 1-triacontanol and mixtures thereof.

6. The composition of claim 5, wherein said fatty alcohol is 1-octadecanol.
7. The composition of claim 2, wherein said sucrose fatty acid ester is selected from the group consisting of sucrose stearate, sucrose distearate, sucrose palmitate and mixtures thereof.
8. The composition of claim 2, wherein said tween is selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, and polysorbate 85.
9. The composition of claim 1, comprising from about 10 to about 99.99 weight percent of said phytosterol and from about 0.01 to about 90 weight percent of said surfactant.
10. The composition of claim 9, comprising from about 40 to about 95 weight percent of said phytosterol and from about 5 to 60 weight percent of said surfactant.
11. The composition of claim 10, comprising about 95 weight percent of said phytosterol and about 5 weight percent of said surfactant.

12. A method of reducing cholesterol absorption in humans which comprises orally administering an effective amount of a mixture of a phytosterol and a surfactant selected from the group consisting of sodium docusate, ammoniated glycyrrhizin, polyoxyethylene castor oil, polyethylene glycol, diacetyl lactic acid esters of mono- and diglycerides, diacetyl tartaric acid esters of mono- and diglycerides, monosodium phosphate derivatives of mono- and diglycerides, ethoxylated mono- and diglycerides, quillaja saponin, ethylene oxide propylene oxide block copolymers, vitamin E TPGS, hydroxylated lecithin and mixtures thereof.
13. The method of claim 12, further comprising a surfactant selected from the group consisting of sodium salts of fatty acids, fatty alcohols, polyethylene glycol (8) stearate, polyethylene glycol (40) stearate, sucrose fatty acid esters, tween and mixtures thereof.
14. The method of claim 12, wherein the phytosterol is selected from the group consisting of sitosterol, campesterol, brassicasterol, stigmasterol, clionasterol and mixtures thereof.
15. The method of claim 14, wherein the sitosterol is alpha-sitosterol or beta-sitosterol.
16. The method of claim 13, wherein said fatty alcohol is selected from the group consisting of 1-decanol, 1-dodecanol, 1-tetradecanol, 1-hexadecanol, 1-

-30-

octadecanol, 9-octadecen-1-ol, 1-eicosanol, 1-docosanol, 1-hexacosanol, 1-octacosanol, 1-triacontanol and mixtures thereof.

17. The method of claim 16, wherein said fatty alcohol is 1-octadecanol.
18. The method of claim 13, wherein said sucrose fatty acid ester is selected from the group consisting of sucrose stearate, sucrose distearate, sucrose palmitate and mixtures thereof.
19. The method of claim 13, wherein said tween is selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, and polysorbate 85.
20. The method of claim 12, comprising from about 10 to about 99.99 weight percent of said phytosterol and from about 0.01 to about 90 weight percent of said surfactant.
21. The method of claim 20, comprising from about 40 to about 95 weight percent of said phytosterol and from about 5 to 60 weight percent of said surfactant.
22. The method of claim 21, comprising about 95 weight percent of said phytosterol and about 5 weight percent of said surfactant.
23. The method of claim 12, wherein said mixture is orally administered in the form of chewable,

-31-

effervescent, swallowable and coated tablets, capsules, soft gelatine capsules, syrup, fruit beverages, granule sachets, fruit gelatines, mini-sweets or sweets.

24. A method for reducing serum cholesterol levels comprising administering a mixture of a phytosterol and a surfactant selected from the group consisting of sodium docusate, ammoniated glycyrrhizin, polyoxyethylene castor oil, polyethylene glycol, diacetyl lactic acid esters of mono- and diglycerides, diacetyl tartaric acid esters of mono- and diglycerides, monosodium phosphate derivatives of mono- and diglycerides, ethoxylated mono- and diglycerides, quillaja saponin, ethylene oxide propylene oxide block copolymers, vitamin E TPGS, hydroxylated lecithin and mixtures thereof.
25. The method of claim 24, further comprising a surfactant selected from the group consisting of sodium salts of fatty acids, fatty alcohols, polyethylene glycol (8) stearate, polyethylene glycol (40) stearate, sucrose fatty acid esters, tween and mixtures thereof.
26. The method of claims 24 or 25, wherein the mixture is administered orally.
27. The method of claim 24, wherein the phytosterol is selected from the group consisting of sitosterol, campesterol, brassicasterol, stigmasterol, clionasterol and mixtures thereof.

28. The method of claim 27, wherein the sitosterol is alpha-sitosterol or beta-sitosterol.
29. The method of claim 25, wherein said fatty alcohol is selected from the group consisting of 1-decanol, 1-dodecanol, 1-tetradecanol, 1-hexadecanol, 1-octadecanol, 9-octadecen-1-ol, 1-eicosanol, 1-docosanol, 1-hexacosanol, 1-octacosanol, 1-triacontanol and mixtures thereof.
30. The method of claim 29, wherein said fatty alcohol is 1-octadecanol.
31. The method of claim 25, wherein said sucrose fatty acid ester is selected from the group consisting of sucrose stearate, sucrose distearate, sucrose palmitate and mixtures thereof.
32. The method of claim 25, wherein said tween is selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, and polysorbate 85.
33. The method of claim 24, comprising from about 10 to about 99.99 weight percent of said phytosterol and from about 0.01 to about 90 weight percent of said surfactant.
34. The method of claim 33, comprising from about 40 to about 95 weight percent of said phytosterol and from about 5 to 60 weight percent of said surfactant.

35. The method of claim 34, comprising about 95 weight percent of said phytosterol and about 5 weight percent of said surfactant.
36. A method for preparing a composition for the reduction of cholesterol absorption, comprising the step of mixing a phytosterol and a surfactant selected from the group consisting of sodium docusate, ammoniated glycyrrhizin, polyoxyethylene castor oil, polyethylene glycol, diacetyl lactic acid esters of mono- and diglycerides, diacetyl tartaric acid esters of mono- and diglycerides, monosodium phosphate derivatives of mono- and diglycerides, ethoxylated mono- and diglycerides, quillaja saponin, ethylene oxide propylene oxide block copolymers, vitamin E TPGS, hydroxylated lecithin and mixtures thereof.
37. The method of claim 36, wherein the mixing is conducted under elevated pressure.
38. The method of claim 37, wherein the mixing is conducted by roller compaction.
39. The method of claim 37, wherein the mixing is conducted in an extruder.
40. The method of claim 36, further comprising a surfactant selected from the group consisting of sodium salts of fatty acids, fatty alcohols, polyethylene glycol (8) stearate, polyethylene

-34-

glycol (40) stearate, sucrose fatty acid esters, tween and mixtures thereof.

41. The method of claim 40, further comprising the step of heating said mixture of said phytosterol and said surfactants to a temperature that results in the formation of a melt.
42. The method of claim 41, further comprising the step of rapidly cooling said melt.
43. The method of claim 42, wherein liquid nitrogen is used for cooling.
44. A food product comprising a mixture of a phytosterol and a surfactant selected from the group consisting of sodium docusate, ammoniated glycyrrhizin, polyoxyethylene castor oil, polyethylene glycol, diacetyl lactic acid esters of mono- and diglycerides, diacetyl tartaric acid esters of mono- and diglycerides, monosodium phosphate derivatives of mono- and diglycerides, ethoxylated mono- and diglycerides, quillaja saponin, ethylene oxide propylene oxide block copolymers, vitamin E TPGS, hydroxylated lecithin and mixtures thereof.
45. The food product of claim 44, further comprising a surfactant selected from the group consisting of sodium salts of fatty acids, fatty alcohols, polyethylene glycol (8) stearate, polyethylene glycol (40) stearate, sucrose fatty acid esters, tween and mixtures thereof.

46. The food product of claim 44, wherein the phytosterol is selected from the group consisting of sitosterol, campesterol, brassicasterol, stigmasterol, clionasterol and mixtures thereof.
47. The food product of claim 46, wherein the sitosterol is alpha-sitosterol or beta-sitosterol.
48. The food product of claim 45, wherein said fatty alcohol is selected from the group consisting of 1-decanol, 1-dodecanol, 1-tetradecanol, 1-hexadecanol, 1-octadecanol, 9-octadecen-1-ol, 1-eicosanol, 1-docosanol, 1-hexacosanol, 1-octacosanol, 1-triacontanol and mixtures thereof.
49. The food product of claim 48, wherein said fatty alcohol is 1-octadecanol.
50. The food product of claim 45, wherein said sucrose fatty acid ester is selected from the group consisting of sucrose stearate, sucrose distearate, sucrose palmitate and mixtures thereof.
51. The food product of claim 45, wherein said tween is selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, and polysorbate 85.
52. The food product of claim 44, comprising from about 10 to about 99.99 weight percent of said phytosterol

-36-

and from about 0.01 to about 90 weight percent of said surfactant.

53. The food product of claim 52, comprising from about 40 to about 95 weight percent of said phytosterol and from about 5 to 60 weight percent of said surfactant.
54. The food product of claim 53, comprising about 95 weight percent of said phytosterol and about 5 weight percent of said surfactant.
55. A composition comprising a mixture of a phytosterol ester and a surfactant selected from the group consisting of sodium docusate, ammoniated glycyrrhizin, polyoxyethylene castor oil, polyethylene glycol, diacetyl lactic acid esters of mono- and diglycerides, diacetyl tartaric acid esters of mono- and diglycerides, monosodium phosphate derivatives of mono- and diglycerides, ethoxylated mono- and diglycerides, quillaja saponin, ethylene oxide propylene oxide block copolymers, vitamin E TPGS, hydroxylated lecithin and mixtures thereof.
56. The composition of claim 55, further comprising a surfactant selected from the group consisting of sodium salts of fatty acids, fatty alcohols, polyethylene glycol (8) stearate, polyethylene glycol (40) stearate, sucrose fatty acid esters, tween and mixtures thereof.

-37-

57. The composition of claim 55, wherein said fatty alcohol is selected from the group consisting of 1-decanol, 1-dodecanol, 1-tetradecanol, 1-hexadecanol, 1-octadecanol, 9-octadecen-1-ol, 1-eicosanol, 1-docosanol, 1-hexacosanol, 1-octacosanol, 1-triacontanol and mixtures thereof.
58. The composition of claim 56, wherein said fatty alcohol is 1-octadecanol.
59. The composition of claim 56, wherein said sucrose fatty acid ester is selected from the group consisting of sucrose stearate, sucrose distearate, sucrose palmitate and mixtures thereof.
60. The composition of claim 56, wherein said tween is selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, and polysorbate 85.
61. The composition of claim 55, comprising from about 10 to about 99.99 weight percent of said phytosterol ester and from about 0.01 to about 90 weight percent of said surfactant.
62. The composition of claim 61, comprising from about 40 to about 95 weight percent of said phytosterol ester and from about 5 to 60 weight percent of said surfactant.

-38-

63. The composition of claim 62, comprising about 95 weight percent of said phytosterol ester and about 5 weight percent of said surfactant.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
10 May 2001 (10.05.2001)

(10) International Publication Number
WO 01/32031 A3

PCT

(51) International Patent Classification⁷: A23L 1/30, 1/035

(21) International Application Number: PCT/US00/30350

(22) International Filing Date:
3 November 2000 (03.11.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/163,383 4 November 1999 (04.11.1999) US
60/198,449 19 April 2000 (19.04.2000) US

(71) Applicant (for all designated States except US): **MON-SANTO TECHNOLOGY LLC** [US/US]: 800 North Lindbergh Boulevard, St. Louis, MO 63167 (US).

(71) Applicants and

(72) Inventors: **MENON, Vinod, P.** [IN/US]: 11567 Tivolin Lane, St. Louis, MO 63146 (US). **KINLEN, Patrick, J.** [US/US]: 1348 Remington Oaks Terrace, St. Louis, MO 63026 (US). **PIRAKITIKULR, Pichai** [IN/US]: 455 Morningside Drive, Crown Point, IN 46307 (US).

(74) Agents: **GOLDEN, Matthew, J.** et al.: Fitzpatrick, Cella, Harper & Scinto, 30 Rockefeller Plaza, New York, NY 10112 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW). Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM). European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR). OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
6 December 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CHOLESTEROL REDUCING STEROL COMPOSITIONS, PREPARATION AND METHOD OF USE

(57) Abstract: A composition comprising a mixture of a phytosterol and/or phytosterol ester and a surfactant(s). The surfactants are selected from the group consisting of anionic, cationic, nonionic, and zwitterionic surfactants. The phytosterol is selected from the group consisting of sitosterol, campesterol, brassicasterol, stigmasterol, clonasterol and mixtures thereof. The phytosterol esters are derivatives of the aforementioned phytosterols. The invention is also directed to a method of making the disclosed compositions, and to non-fat containing food products including the disclosed compositions.

WO 01/32031 A3

INTERNATIONAL SEARCH REPORT

Int. l. Application No

PCT/US 00/30350

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A23L1/30 A23L1/035

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A23L A23D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, FSTA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 897 671 A (UNILEVER PLC ;UNILEVER NV (NL)) 24 February 1999 (1999-02-24) cited in the application	1,3,4, 8-10,24, 26-28, 32-34, 36,41, 42,44, 46,47, 52,53, 55,61,62
A	claims 1,4-7,10,15,16,25-27; examples 1,3,6 page 4, line 2-13,52 -page 5, line 1,9-19 page 7, line 4-12	2,5-7, 11,25, 29-31, 35, 37-40, 45, 48-51,
	-/--	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

9 March 2001

Date of mailing of the international search report

14. 03. 2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Tallgren, A

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/30350

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	<p style="text-align: center;">---</p> <p>WO 00 47213 A (UNIV WASHINGTON) 17 August 2000 (2000-08-17)</p>	<p>54, 56-60, 63</p>
A	<p>claims 1,5,11-14; examples 1,6; tables 1,6 page 4, line 22 -page 5, line 9,15-27 page 6, line 22 -page 7, line 15</p>	<p>1,3,4,9, 10,24, 26-28, 33,34, 36,37, 41,42, 44,46, 47,52,53</p>
A	<p style="text-align: center;">---</p> <p>US 5 244 887 A (STRAUB CARL D) 14 September 1993 (1993-09-14) cited in the application claims 1,2 column 1, line 8-12 column 4, line 40-47 column 6, line 10-22 column 7, line 10-17</p>	<p>2,5-8, 11,25, 29-32, 35, 38-40, 43,45, 48-51, 54-63</p>
A	<p style="text-align: center;">---</p> <p>EP 0 289 636 A (ASAHI DENKA KOGYO KK ;AJINOMOTO KK (JP)) 9 November 1988 (1988-11-09) claims 1,2,7; examples 1,2; table 1 page 2, line 8-11,50 -page 3, line 22,40-52</p>	<p>1-11, 24-63</p>
P, A	<p style="text-align: center;">---</p> <p>WO 00 45648 A (FORBES MEDI TECH INC) 10 August 2000 (2000-08-10) claims 1,3,4; example 2 page 1, paragraph 1 page 7, paragraph 1 page 10, line 4 -page 11, line 1,2 page 12, paragraph 4 -page 13, paragraph 2</p>	<p>1-11, 24-63</p>
P, A	<p style="text-align: center;">---</p> <p>EP 0 986 962 A (MCNEIL PPC INC) 22 March 2000 (2000-03-22) claims 1,4,5,7,9,10 page 2, line 34,35 page 3, line 1-5,19</p> <p style="text-align: center;">-----</p>	<p>1-11, 24-63</p>

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 00/30350

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 12-23
because they relate to subject matter not required to be searched by this Authority, namely:
Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. l. Application No

PCT/US 00/30350

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0897671	A	24-02-1999	BR 9803191 A CA 2245467 A JP 11146757 A	11-01-2000 22-02-1999 02-06-1999
WO 0047213	A	17-08-2000	US 6063776 A AU 3231300 A	16-05-2000 29-08-2000
US 5244887	A	14-09-1993	NONE	
EP 0289636	A	09-11-1988	JP 62186936 A	15-08-1987
WO 0045648	A	10-08-2000	AU 2426500 A	25-08-2000
EP 0986962	A	22-03-2000	US 6123978 A AU 4463699 A BR 9903979 A JP 2000102361 A NO 994195 A	26-09-2000 16-03-2000 05-09-2000 11-04-2000 01-03-2000